AVTX Avalo Therapeutics
Price Chart
Executive Summary
Avalo Therapeutics priced a $375M underwritten public offering of 19.73M shares at $17.75/share plus pre-funded warrants, representing massive dilution of ~54% of current shares outstanding. The proceeds will fund Phase 3 development of lead asset abdakibart for hidradenitis suppurativa, but the dilutive structure and the company's clinical-stage profile create significant downside risk for existing shareholders.
Key Financial Metrics
Actionable Insight
Massive dilutive offering at a ~2% discount to the prior close signals urgent capital needs and likely near-term selling pressure. Monitor for the underwriters' option exercise and any further insider selling. The Phase 3 data readout for abdakibart is the key catalyst but is now further out given the capital raise timeline.
Key Facts
- Priced 19,730,000 shares of common stock at $17.75 per share plus pre-funded warrants for 1,400,000 shares at $17.749 each
- Gross proceeds expected to be approximately $375 million
- Underwriters have 30-day option to purchase up to an additional 3,169,500 shares
- Offering expected to close May 7, 2026
- Proceeds to fund clinical development of abdakibart (AVTX-009) through Phase 3 topline data release
- Dilution of approximately 54% based on current shares outstanding (pre-offering market cap $368M)
- Joint bookrunners: Leerink Partners, TD Cowen, BofA Securities, Piper Sandler, Cantor
Financial Impact
$375 million gross proceeds with ~54% dilution to existing shareholders based on current market cap of $368M
Risk Factors
- 54% dilution will significantly depress EPS and ownership stakes
- Clinical-stage biotech with no approved products — high execution risk on abdakibart
- Underwriters' option could add further dilution of ~16% more shares
- Historical model performance on AVTX shows negative returns at T+20, suggesting persistent downside pressure
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3288460 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
May 13, 2026
10d ago
|
8-K
| $19.85 $16.27 | ▼ −18.04% | ▼ −16.88% | $16.35 (−17.63%) |
|
May 13, 2026
10d ago
|
Press Release
| $19.85 $16.27 | ▼ −18.04% | ▼ −16.88% | $16.35 (−17.63%) |
|
May 6, 2026
17d ago
|
Press Release
| $21.81 $19.94 | ▲ +8.57% | ▲ +9.71% | $16.35 (+25.03%) |
|
May 6, 2026
18d ago
|
Insider Cluster
| $21.81 $19.94 | ▲ +8.57% | ▲ +9.71% | $16.35 (+25.03%) |
|
May 5, 2026
18d ago
|
424B5
| $21.81 $19.94 | ▼ −8.57% | ▼ −9.71% | $16.35 (−25.03%) |
|
May 5, 2026
18d ago
|
Press Release
| $21.81 $19.94 | ▼ −8.57% | ▼ −9.71% | $16.35 (−25.03%) |
|
Apr 10, 2026
6w ago
|
DEFA14A
| $13.34 $14.66 | ▲ +9.90% | ▲ +6.60% | $16.35 (+22.56%) |
|
Apr 2, 2026
7w ago
|
Insider Cluster
| $17.76 $13.66 | ▼ −23.09% | ▼ −26.70% | $16.35 (−7.94%) |
|
Apr 1, 2026
7w ago
|
Insider Cluster
| $16.70 $14.21 | ▼ −14.91% | ▼ −18.68% | $16.35 (−2.10%) |
|
Mar 23, 2026
8w ago
|
Press Release
| $13.50 $13.93 | ▼ −3.19% | ▼ −6.75% | $16.35 (−21.11%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access